Literature DB >> 17515959

Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells.

Galatea Kallergi1, Dimitris Mavroudis, Vassilis Georgoulias, Christos Stournaras.   

Abstract

Several markers have been used to detect circulating tumor cells (CTC) in the peripheral blood of patients with breast cancer. However, analysis of activated signaling kinases in CTC implicated in cellular transformation, migration, and survival has not been addressed so far. In the present study, we focused on the phenotypic profile of micrometastatic cells in peripheral blood mononuclear cells (PBMC) preparations from 45 breast cancer patients. PBMC cytospins from 28 cytokeratin (CK)-positive and 17 CK-negative samples were assessed for the expression of phosphorylated FAK (p-FAK), phosphorylated PI-3 kinase (p-PI-3K), and HER2 using confocal laser scanning microscopy. The expression of p-FAK was documented in all 28 CK-positive samples, while all 17 CK-negative samples were tested negative for p-FAK. Immunomagnetic separation using EpCAM antibody fully confirmed these findings, implying a sound correlation for the co-expression of the two molecules. Interestingly, 15 of 28 CK- and p-FAK-positive samples also expressed the HER2 oncoprotein. p-PI-3K was documented in 15 of 17 CK- and p-FAK-positive samples. Immunoblot analysis of micrometastatic cells in co-culture with PBMC confirmed the specific expression of both p-FAK and p-PI-3K. Finally, impaired actin organization was apparent in CK- and p-FAK/p-PI-3K-positive samples, comparable to that observed in MCF-7 human breast cancer cells. Our findings provide strong evidence that micrometastatic cells express activated signaling kinases, which may regulate migration mechanisms, supporting the presumption of their malignant and metastatic nature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17515959      PMCID: PMC1869618          DOI: 10.2119/2006-00083.Kallergi

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  41 in total

Review 1.  Actin cytoskeleton and cell signaling.

Authors:  C L Carpenter
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

2.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

3.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.

Authors:  S Braun; C Kentenich; W Janni; F Hepp; J de Waal; F Willgeroth; H Sommer; K Pantel
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

Review 4.  Biochemical signals and biological responses elicited by the focal adhesion kinase.

Authors:  M D Schaller
Journal:  Biochim Biophys Acta       Date:  2001-07-25

5.  ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.

Authors:  S Braun; G Schlimok; I Heumos; G Schaller; L Riethdorf; G Riethmüller; K Pantel
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase.

Authors:  H C Chen; P A Appeddu; H Isoda; J L Guan
Journal:  J Biol Chem       Date:  1996-10-18       Impact factor: 5.157

8.  HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.

Authors:  Pia Wülfing; Julia Borchard; Horst Buerger; Stefan Heidl; Kurt S Zänker; Ludwig Kiesel; Burkhard Brandt
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

9.  Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system.

Authors:  Aliki Stathopoulou; Anna Gizi; Maria Perraki; Stella Apostolaki; Nikos Malamos; Dimitris Mavroudis; Vassilis Georgoulias; Evi S Lianidou
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

10.  Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention.

Authors:  S Braun; N Harbeck
Journal:  Expert Rev Mol Med       Date:  2001-09-06       Impact factor: 5.600

View more
  37 in total

1.  Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas.

Authors:  Vanisri Raviraj; Hui Zhang; Hsin-ya Chien; Louise Cole; Erik W Thompson; Lilian Soon
Journal:  Clin Exp Metastasis       Date:  2012-01-22       Impact factor: 5.150

2.  Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers.

Authors:  Tiffany A Wallace; Ronan F Downey; Caleb J Seufert; Aaron Schetter; Tiffany H Dorsey; Carol A Johnson; Radoslav Goldman; Christopher A Loffredo; Peisha Yan; Francis J Sullivan; Francis J Giles; Feng Wang-Johanning; Stefan Ambs; Sharon A Glynn
Journal:  Carcinogenesis       Date:  2014-05-23       Impact factor: 4.944

Review 3.  Proteomic research progress in lymphatic metastases of cancers.

Authors:  Junwei Zong; Chunmei Guo; Shuqing Liu; Ming-Zhong Sun; Jianwu Tang
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

Review 4.  The role of FAK in tumor metabolism and therapy.

Authors:  Jianliang Zhang; Steven N Hochwald
Journal:  Pharmacol Ther       Date:  2013-12-09       Impact factor: 12.310

5.  Detection of circulating tumor cells: Clinical relevance of a novel metastatic tumor marker.

Authors:  Chuanli Ren; Chongxu Han; Daxin Wang; Xiaohang Zhao; Guangfu Jin; Hongbing Shen
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

6.  Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine.

Authors:  Sayaka Kemmochi; Hitoshi Fujimoto; Gye-Hyeong Woo; Kaoru Inoue; Miwa Takahashi; Kunitoshi Mitsumori; Masao Hirose; Akiyoshi Nishikawa; Makoto Shibutani
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-26       Impact factor: 4.553

7.  Ethanol enhances the interaction of breast cancer cells over-expressing ErbB2 with fibronectin.

Authors:  Mei Xu; Kimberly A Bower; Gang Chen; Xianglin Shi; Zheng Dong; Zunji Ke; Jia Luo
Journal:  Alcohol Clin Exp Res       Date:  2010-03-01       Impact factor: 3.455

8.  Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.

Authors:  Jeffrey B Smerage; G Thomas Budd; Gerald V Doyle; Marty Brown; Costanza Paoletti; Maria Muniz; M Craig Miller; Madeline I Repollet; David A Chianese; Mark C Connelly; Leon W W M Terstappen; Daniel F Hayes
Journal:  Mol Oncol       Date:  2013-03-14       Impact factor: 6.603

9.  Periostin induces intracellular cross-talk between kinases and hyaluronan in atrioventricular valvulogenesis.

Authors:  Shibnath Ghatak; Suniti Misra; Russell A Norris; Ricardo A Moreno-Rodriguez; Stanley Hoffman; Robert A Levine; Vincent C Hascall; Roger R Markwald
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

10.  Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.

Authors:  Galatea Kallergi; Harris Markomanolaki; Vicky Giannoukaraki; Maria A Papadaki; Areti Strati; Evi S Lianidou; Vassilis Georgoulias; Dimitris Mavroudis; Sofia Agelaki
Journal:  Breast Cancer Res       Date:  2009-11-17       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.